Nanoparticle-based passive drug targeting to tumors: considerations and implications for optimization

Area of Science:

• Pharmacology
• Biomedical Engineering
• Oncology

Background:

• Conventional small-molecule chemotherapeutics often exhibit poor tissue specificity and narrow therapeutic indices due to widespread distribution in healthy tissues.
• Solid tumors present significant barriers to effective drug delivery, limiting treatment efficacy.
• Nanoparticle-based drug delivery systems are emerging as a promising strategy to overcome these limitations.

Purpose of the Study:

• To review recent findings on passive drug targeting strategies using nanoparticles for solid tumor treatment.
• To discuss the application of passive targeting in anti-angiogenic therapy.
• To provide considerations and implications for the rational design of passive drug targeting strategies.

Main Methods:

• Review of preclinical studies on nanoparticle-mediated drug targeting.
• Analysis of passive drug targeting concepts and their efficacy.
• Exploration of nanoparticle applications in anti-angiogenic therapy.

Main Results:

• Passive drug targeting, exploiting the enhanced permeability and retention (EPR) effect, has shown significant promise in preclinical studies.
• Nanoparticle formulations can improve the accumulation of chemotherapeutics within tumor tissues.
• Passive targeting strategies are applicable to various therapeutic approaches, including anti-angiogenic therapy.

Conclusions:

• Passive nanoparticle targeting represents a viable strategy to enhance the delivery of small-molecule drugs to solid tumors.
• Careful consideration of nanoparticle design and tumor characteristics is crucial for optimizing passive targeting efficacy.
• Further research into rational design principles will advance the clinical translation of nanoparticle-based tumor-targeted therapies.